NL301146I1 - Vericiguat - Google Patents
VericiguatInfo
- Publication number
- NL301146I1 NL301146I1 NL301146C NL301146C NL301146I1 NL 301146 I1 NL301146 I1 NL 301146I1 NL 301146 C NL301146 C NL 301146C NL 301146 C NL301146 C NL 301146C NL 301146 I1 NL301146 I1 NL 301146I1
- Authority
- NL
- Netherlands
- Prior art keywords
- vericiguat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010021637A DE102010021637A1 (de) | 2010-05-26 | 2010-05-26 | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
PCT/EP2011/058431 WO2011147809A1 (de) | 2010-05-26 | 2011-05-24 | Substituierte 5-fluor-1h-pyrazolopyridine und ihre verwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
NL301146I1 true NL301146I1 (nl) | 2021-12-08 |
NL301146I2 NL301146I2 (nl) | 2022-07-06 |
Family
ID=44119218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL301146C NL301146I2 (nl) | 2010-05-26 | 2021-12-01 | Vericiguat |
Country Status (45)
Families Citing this family (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008063992A1 (de) * | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
ES2524826T3 (es) | 2009-11-27 | 2014-12-12 | Bayer Intellectual Property Gmbh | Procedimiento para la purificación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo |
WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EP2575473B1 (en) | 2010-05-27 | 2016-01-20 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP2682394A1 (de) | 2010-07-09 | 2014-01-08 | Bayer Intellectual Property GmbH | 1H-Pyrazolo[3,4-b]pyridin-Triazine Verbindungen und ihre Verwendung zur Behandlung bzw. Prophylaxe von Herz-Kreislauf-Erkrankungen |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
WO2012143510A1 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung |
EP2594270A3 (en) * | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
DK2782914T3 (en) | 2011-11-25 | 2018-11-26 | Adverio Pharma Gmbh | PROCEDURE FOR PREPARING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPYRIDINES |
CN102491974B (zh) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法 |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
DE102012200349A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
DE102012200352A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
ES2644781T3 (es) | 2012-03-06 | 2017-11-30 | Bayer Intellectual Property Gmbh | Azabiciclos sustituidos y su uso |
WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
CA2879456A1 (en) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralincarboxylic acids and use thereof |
PT2875003T (pt) | 2012-07-20 | 2017-02-16 | Bayer Pharma AG | Novos ácidos 5-amino-tetra-hidroquinolina-2-carboxílicos e sua utilização |
TW201439090A (zh) | 2012-11-30 | 2014-10-16 | Astellas Pharma Inc | 咪唑並吡啶化合物 |
AU2014220801A1 (en) | 2013-02-21 | 2015-09-10 | Adverio Pharma Gmbh | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
CN105308055B (zh) | 2013-03-01 | 2017-07-14 | 拜耳制药股份公司 | 三氟甲基取代的稠合嘧啶类及其用途 |
JP2016522231A (ja) | 2013-06-21 | 2016-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | ジアミノヘテロアリール置換ピラゾール類 |
PE20160201A1 (es) | 2013-07-10 | 2016-05-06 | Bayer Pharma AG | Bencil-1h-pirazol[3,4-b]piridinas y su uso |
EP3024455A1 (en) | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
US20160221965A1 (en) | 2013-09-16 | 2016-08-04 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluoromethyl pyrimidinones and their use |
KR20160065957A (ko) | 2013-10-07 | 2016-06-09 | 바이엘 파마 악티엔게젤샤프트 | 시클릭 티에노우라실-카르복스아미드 및 그의 용도 |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP3079701B1 (en) | 2013-12-11 | 2021-08-11 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
CN106661008A (zh) | 2014-04-03 | 2017-05-10 | 拜耳制药股份公司 | 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸 |
US20170119776A1 (en) | 2014-04-03 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
EP3152214B1 (en) | 2014-06-04 | 2020-01-29 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
CN107074773A (zh) | 2014-09-09 | 2017-08-18 | 拜耳制药股份公司 | 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途 |
ES2712886T3 (es) | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
SG11201703199UA (en) | 2014-11-03 | 2017-05-30 | Bayer Pharma AG | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之***并吡基衍生物 |
WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
EA201792346A1 (ru) | 2015-05-06 | 2018-05-31 | Байер Фарма Акциенгезельшафт | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc) |
WO2016191334A1 (en) | 2015-05-27 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
SI3325013T2 (sl) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba |
WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
AU2016365676A1 (en) | 2015-12-10 | 2018-06-07 | Bayer Pharma Aktiengesellschaft | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of TASK-1 and TASK-2 channels, for the treatment of sleep-related breathing disorders |
EA201891416A1 (ru) | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
CN105461715B (zh) * | 2015-12-15 | 2017-03-29 | 郑州大明药物科技有限公司 | 一种利奥西呱中间体的合成方法 |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
WO2017121692A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituierte sulfamide und ihre verwendung |
WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
WO2017191105A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
EP3452470B1 (en) | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
EP3452472A1 (en) | 2016-05-03 | 2019-03-13 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
WO2017191115A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
JOP20170113B1 (ar) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
WO2017200857A1 (en) | 2016-05-18 | 2017-11-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
JP2019524722A (ja) | 2016-07-11 | 2019-09-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 7−置換1−ピリジル−ナフチリジン−3−カルボン酸アミドおよびその使用 |
JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
KR20190053242A (ko) | 2016-09-23 | 2019-05-17 | 바이엘 악티엔게젤샤프트 | N3-시클릭 치환된 티에노우라실 및 그의 용도 |
JP7237823B2 (ja) | 2016-10-11 | 2023-03-13 | バイエル ファーマ アクチエンゲゼルシャフト | Sgcアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ |
US10918639B2 (en) | 2016-10-11 | 2021-02-16 | Bayer Pharma Aktiengesellschaft | Combination containing SGC stimulators and mineralocorticoid receptor antagonists |
JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
EP3338803A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
EP3338764A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
WO2018153899A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
PE20191616A1 (es) | 2017-04-10 | 2019-11-05 | Bayer Ag | N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso |
AU2018252099B2 (en) | 2017-04-11 | 2021-08-12 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
CN108690016B (zh) * | 2017-04-11 | 2022-08-12 | 广东东阳光药业有限公司 | 吡唑并吡啶类化合物及其用途 |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
CA3079770A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
WO2019081302A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
CN111225917A (zh) * | 2017-10-24 | 2020-06-02 | 拜耳股份公司 | 取代咪唑并吡啶酰胺及其用途 |
LT3700913T (lt) | 2017-10-24 | 2022-01-25 | Bayer Aktiengesellschaft | Pakeistojo triazolo darinių provaistai ir jų naudojimas |
WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
CA3079771A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
WO2019081307A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
US11149023B2 (en) | 2017-10-24 | 2021-10-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
US11337973B2 (en) | 2017-11-07 | 2022-05-24 | Bayer Aktiengesellschaft | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors |
MX2020005646A (es) | 2017-12-01 | 2020-08-20 | Bayer Pharma AG | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico. |
JP7337067B2 (ja) * | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC刺激薬 |
EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
EP3566704A1 (en) | 2018-05-11 | 2019-11-13 | Bayer Aktiengesellschaft | The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases |
BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
EA202092779A1 (ru) | 2018-05-17 | 2021-02-02 | Байер Акциенгезельшафт | Замещенные дигидропиразолопиразинкарбоксамидные производные |
US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
US20210177846A1 (en) | 2018-07-11 | 2021-06-17 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
CA3107174A1 (en) | 2018-07-24 | 2020-01-30 | Bayer Aktiengesellschaft | Pharmaceutical dosage form which can be administered orally and has modified release |
MX2021000904A (es) | 2018-07-24 | 2021-03-31 | Bayer Ag | Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada. |
PE20211285A1 (es) | 2018-11-27 | 2021-07-19 | Bayer Ag | Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios |
TWI830835B (zh) | 2018-12-17 | 2024-02-01 | 德商亞德維瑞醫藥有限公司 | 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物 |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
SG11202111587VA (en) | 2019-05-07 | 2021-11-29 | Bayer Ag | Masp inhibitory compounds and uses thereof |
TW202112359A (zh) | 2019-06-07 | 2021-04-01 | 德商拜耳廠股份有限公司 | sGC活化劑於治療眼科疾病之用途 |
MX2022005414A (es) | 2019-11-06 | 2022-05-26 | Bayer Ag | Inhibidores de adrenoreceptor adrac2. |
WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
JP2023514532A (ja) * | 2020-02-03 | 2023-04-06 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | メチル{4,6-ジアミノ-2-[5-フルオロ-1-(2-フルオロベンジル)-1H-ピラゾロ[3,4-b]ピリジン-3-イル]ピリミジン-5-イル}カルバメートのナノ製剤 |
CA3170507A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
CA3170508A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
US20230130739A1 (en) | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
EP3925953A1 (en) | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
CA3200103A1 (en) | 2020-11-04 | 2022-05-12 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
CN116710439A (zh) | 2020-12-10 | 2023-09-05 | 拜耳公司 | 取代的吡唑并哌啶羧酸 |
EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
WO2022122917A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
EP4011874A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
CN116829545A (zh) | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
EP4326268A1 (en) | 2021-04-20 | 2024-02-28 | Tisento Therapeutics Inc. | Treatment of cns diseases with sgc stimulators |
BR112023021851A2 (pt) | 2021-04-20 | 2024-02-06 | Tisento Therapeutics Inc | Estimulantes de sgc |
WO2023034364A1 (en) | 2021-08-31 | 2023-03-09 | Teva Pharmaceuticals International Gmbh | Solid state forms of vericiguat and process for preparation thereof |
WO2023126438A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Pharmaceutical dry powder inhalation formulation |
TW202342034A (zh) | 2021-12-29 | 2023-11-01 | 德商拜耳廠股份有限公司 | 心肺病症之治療 |
AR128147A1 (es) | 2021-12-29 | 2024-03-27 | Bayer Ag | Procedimiento para la preparación del ácido (5s)-[2-(4-carboxifenil)etil][2-(2-[3-cloro-4-(trifluorometil)bifenil-4-il]metoxifenil)etil]amino-5,6,7,8-tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo |
ES2956054A1 (es) * | 2022-05-03 | 2023-12-12 | Moehs Iberica Sl | 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
WO2024086179A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics, Inc. | Pyrimidine sgc stimulators |
WO2024086182A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
CN117924280A (zh) * | 2024-03-20 | 2024-04-26 | 中国人民解放军军事科学院军事医学研究院 | 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01198481A (ja) * | 1988-02-01 | 1989-08-10 | Canon Inc | マイクロ波プラズマcvd法による堆積膜形成法 |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
EP0463754A1 (en) | 1990-06-25 | 1992-01-02 | Rohm And Haas Company | Stabilization of glutarimide polymers |
DK181190D0 (da) | 1990-07-30 | 1990-07-30 | Lundbeck & Co As H | 3-aryl-indol- eller 3-aryl-indazolderivater |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
PL332871A1 (en) | 1996-10-14 | 1999-10-25 | Bayer Ag | Novel heterocyclylmethyl-substituted derivative of pyrazole |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
US6008243A (en) | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP2295436A1 (de) | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren |
US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
GB0002666D0 (en) | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
JP4295505B2 (ja) | 2000-11-22 | 2009-07-15 | バイエル アクチェンゲゼルシャフト | 新規なラクタム置換ピラゾロピリジン誘導体 |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
CA2464333C (en) | 2001-10-26 | 2011-07-26 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2003076408A2 (en) | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
GR1004350B (el) * | 2002-03-29 | 2003-09-26 | Συσκευη εισπνοων ξηρης σκονης | |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
DE10232571A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-Aminosubstituierte Pyrimidinderivate |
DE10242941A1 (de) | 2002-09-16 | 2004-03-18 | Bayer Ag | Substituiertes Pyrazolderivat |
DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
EP4059923A1 (en) | 2002-11-20 | 2022-09-21 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
WO2004099149A1 (ja) | 2003-05-09 | 2004-11-18 | Asahi Glass Company, Limited | 2-クロロ-5-フルオロ-3-置換ピリジンまたはその塩の製造方法 |
WO2005030121A2 (en) | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds, compositions and methods |
PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
CN100355732C (zh) | 2003-11-03 | 2007-12-19 | 上海药明康德新药开发有限公司 | 2-氯-5-氟-烟酸酯及酸的制备方法 |
DE10351903A1 (de) | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
GB0403819D0 (en) | 2004-02-20 | 2004-03-24 | Merck Sharp & Dohme | New compounds |
US7514463B2 (en) | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
WO2006037491A1 (en) | 2004-10-05 | 2006-04-13 | Bayer Healthcare Ag | A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction |
DE102005047945A1 (de) | 2005-07-16 | 2007-01-18 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen |
RU2008105481A (ru) | 2005-07-18 | 2009-08-27 | Байер ХельсКер АГ (DE) | Новое применение активаторов и стимуляторов растворимой гуанилатциклазыдля профилактики или лечения почечных расстройств |
DE102006021733A1 (de) | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
EP2170884A2 (en) | 2007-06-25 | 2010-04-07 | Boehringer Ingelheim International GmbH | Chemical compounds |
CN101790532B (zh) | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 5-氟-1H-吡唑并[3,4-b]吡啶-3-胺及其衍生物的制备方法 |
JP2011513483A (ja) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
DE102008063992A1 (de) * | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
AR077898A1 (es) | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
UY33040A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pahrma Akitengesellschaft | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo |
UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
ES2524826T3 (es) | 2009-11-27 | 2014-12-12 | Bayer Intellectual Property Gmbh | Procedimiento para la purificación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo |
WO2011075655A1 (en) | 2009-12-18 | 2011-06-23 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating peripheral vascular disease |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
DE102010021637A1 (de) * | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
CA2955143C (en) * | 2010-05-26 | 2020-02-11 | Claudia Hirth-Dietrich | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc). |
EP2575473B1 (en) | 2010-05-27 | 2016-01-20 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP2682394A1 (de) | 2010-07-09 | 2014-01-08 | Bayer Intellectual Property GmbH | 1H-Pyrazolo[3,4-b]pyridin-Triazine Verbindungen und ihre Verwendung zur Behandlung bzw. Prophylaxe von Herz-Kreislauf-Erkrankungen |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010040234A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
WO2012166390A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
AP2014007541A0 (en) | 2011-09-02 | 2014-03-31 | Bayer Ip Gmbh | Substituted annellated pyrimidine and the use thereof |
DK2782914T3 (en) | 2011-11-25 | 2018-11-26 | Adverio Pharma Gmbh | PROCEDURE FOR PREPARING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPYRIDINES |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
-
2010
- 2010-05-26 DE DE102010021637A patent/DE102010021637A1/de not_active Withdrawn
-
2011
- 2011-05-19 UY UY0001033396A patent/UY33396A/es active IP Right Grant
- 2011-05-19 US US13/111,856 patent/US8420656B2/en active Active
- 2011-05-24 AU AU2011257335A patent/AU2011257335B2/en active Active
- 2011-05-24 RS RS20160263A patent/RS54704B1/en unknown
- 2011-05-24 SI SI201130781A patent/SI2576547T1/sl unknown
- 2011-05-24 CA CA2800697A patent/CA2800697C/en active Active
- 2011-05-24 SG SG2012082152A patent/SG185460A1/en unknown
- 2011-05-24 BR BR122020023470-9A patent/BR122020023470B1/pt active IP Right Grant
- 2011-05-24 PE PE2012002172A patent/PE20130402A1/es active IP Right Grant
- 2011-05-24 EA EA201291336A patent/EA023631B9/ru not_active IP Right Cessation
- 2011-05-24 CN CN201180026010.7A patent/CN102939289B/zh active Active
- 2011-05-24 ME MEP-2016-64A patent/ME02393B/me unknown
- 2011-05-24 KR KR1020127033601A patent/KR101862420B1/ko active IP Right Grant
- 2011-05-24 MY MYPI2012700999A patent/MY164356A/en unknown
- 2011-05-24 CU CU2012000161A patent/CU24086B1/es active IP Right Grant
- 2011-05-24 BR BR112012030010-5A patent/BR112012030010A2/pt not_active Application Discontinuation
- 2011-05-24 JP JP2013511643A patent/JP5896991B2/ja active Active
- 2011-05-24 WO PCT/EP2011/058431 patent/WO2011147809A1/de active Application Filing
- 2011-05-24 EP EP11720806.6A patent/EP2576547B1/de active Active
- 2011-05-24 DK DK11720806.6T patent/DK2576547T3/en active
- 2011-05-24 MA MA35391A patent/MA34248B1/fr unknown
- 2011-05-24 JO JOP/2011/0171A patent/JO3199B1/ar active
- 2011-05-24 HU HUE11720806A patent/HUE026912T2/en unknown
- 2011-05-24 PL PL11720806T patent/PL2576547T3/pl unknown
- 2011-05-24 NZ NZ603800A patent/NZ603800A/en unknown
- 2011-05-24 MX MX2012013324A patent/MX2012013324A/es active IP Right Grant
- 2011-05-24 AR ARP110101777A patent/AR081628A1/es active IP Right Grant
- 2011-05-24 ES ES11720806.6T patent/ES2567795T3/es active Active
- 2011-05-24 UA UAA201214902A patent/UA109660C2/uk unknown
- 2011-05-25 TW TW100118222A patent/TWI516263B/zh active
-
2012
- 2012-11-15 IL IL223050A patent/IL223050A/en active IP Right Grant
- 2012-11-16 CO CO12208156A patent/CO6640226A2/es active IP Right Grant
- 2012-11-20 CL CL2012003226A patent/CL2012003226A1/es unknown
- 2012-11-21 GT GT201200313A patent/GT201200313A/es unknown
- 2012-11-23 TN TNP2012000549A patent/TN2012000549A1/en unknown
- 2012-11-23 DO DO2012000299A patent/DOP2012000299A/es unknown
- 2012-11-26 EC ECSP12012310 patent/ECSP12012310A/es unknown
- 2012-11-26 CR CR20120596A patent/CR20120596A/es unknown
-
2013
- 2013-03-27 US US13/851,373 patent/US8921377B2/en active Active
- 2013-08-15 HK HK13109548.3A patent/HK1182112A1/zh unknown
-
2014
- 2014-11-24 US US14/552,122 patent/US9266885B2/en active Active
-
2016
- 2016-01-15 US US14/996,678 patent/US20160129004A1/en not_active Abandoned
- 2016-04-11 HR HRP20160370TT patent/HRP20160370T1/hr unknown
- 2016-04-12 CY CY20161100301T patent/CY1117372T1/el unknown
- 2016-11-10 US US15/348,545 patent/US9993476B2/en active Active
- 2016-12-20 IL IL249669A patent/IL249669B/en active IP Right Grant
-
2018
- 2018-05-16 US US15/981,598 patent/US10736896B2/en active Active
-
2020
- 2020-07-02 US US16/919,385 patent/US11439642B2/en active Active
-
2021
- 2021-08-26 LT LTPA2021518C patent/LTC2576547I2/lt unknown
- 2021-08-27 HU HUS2100032C patent/HUS2100032I1/hu unknown
- 2021-08-30 FR FR21C1038C patent/FR21C1038I2/fr active Active
- 2021-09-06 NO NO2021032C patent/NO2021032I1/no unknown
- 2021-12-01 NL NL301146C patent/NL301146I2/nl unknown
-
2022
- 2022-08-18 US US17/820,667 patent/US20220409618A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE102011100241A8 (de) | Nitridhalbleiterbauteil | |
DK3225404T3 (da) | Fluidpatron | |
CR20130111A (es) | Triazina-oxidiazoles | |
DE10170954T8 (de) | Mikrowellendruckgarer | |
DE112011104226A5 (de) | Käfigmutter | |
DE102011117046A8 (de) | Doppelkupplungswindungsgetriebe | |
DE112011101226A5 (de) | Linearwegmesssystem | |
DE112011102080A5 (de) | Kupplungszentralausrücker | |
DK2442899T3 (da) | Rotorskive | |
DK2539163T3 (da) | Dækventil | |
DE102011002623A8 (de) | Ventilsteuerzeitversteller | |
DE112011102711A5 (de) | Hydrostataktor | |
DK2448659T3 (da) | Rotorskive | |
DK2447426T3 (da) | Vaske-WC | |
DE102010019119B8 (de) | Cuttermesser | |
DE112010005518A5 (de) | Dichtungsmanchette | |
DE102010038420A8 (de) | Reinigungungsvorrichtung | |
DK2596072T3 (da) | Bor-forbindelses-suspension | |
DK2521486T3 (da) | Palpometer | |
CO6801789A2 (es) | N-hetarilmetil pirazolilcarboxamidas | |
DE112011101796A5 (de) | Redoxakkumulatoranlage | |
DE102010035554B8 (de) | Fußtüröffner | |
DK2404809T3 (da) | Trækbjælke | |
DE112011104385A5 (de) | Tierleiteinrichtung | |
DE102010037356B8 (de) | Verdichterradkühlung |